Elekta stock gains as UBS reiterates sell rating after first-quarter results

Elekta stock (ISIN SE0000163628) is trading close to a new 52-week high on Nasdaq Stockholm, with recent indicative prices around 16.28 SEK as of September 8, 2026, reflecting a gain of roughly 77 percent since the beginning of the year according to market data.MarketScreener The strong share performance contrasts with cautious analyst commentary following Elekta's latest first-quarter report. UBS sticks to sell rating after Q1 Per a note dated September 8, 2026, UBS has reiterated its sell recommendation on medical technology group Elekta and maintained a price target of 41 SEK after reviewing the company's first-quarter results.MarketScreener The bank highlights that its forecasts for Elekta's adjusted operating profit for the current fiscal year are about 4 percent below the market consensus, and for subsequent years the gap widens to an average of roughly 8 percent.MarketScreener According to the same analysis, China accounts for around 13 percent of Elekta's sales, but revenues in this market fell by about 15 percent year on year in the latest quarter due to continued installation delays.MarketScreener UBS also points to competitive pressure from the planned launch of a new Varian platform on September 27, 2026, arguing that key product milestones in the sector could weigh on the relative appeal of Elekta stock if the company does not keep pace with innovation.MarketScreener Share price strength versus sector valuation Recent market data show Elekta stock trading around 16.28 SEK, with an indicative 52-week high near 15.95 SEK and a market capitalization of approximately 226 million SEK as of September 8, 2026.MarketScreener That implies the current share price is slightly above the referenced indicative yearly high range and far above levels seen a year ago, supporting the statement that the stock has risen roughly 73 to 77 percent over the period.MarketScreener UBS notes that Elekta shares trade at a discount of about 20 percent to the sector's price-earnings ratio, compared with the company's three-year historical average discount of around 30 percent.MarketScreener For investors, this means that while Elekta stock still appears cheaper than some peers on a headline valuation basis, the discount has narrowed, and UBS does not see sufficient upside to change its cautious stance given operational risks and competitive dynamics. First-quarter performance and regional challenges In the first quarter of its current fiscal year, Elekta reported a decline in revenue in China of around 15 percent year on year, as installation delays slowed the recognition of sales despite underlying demand for radiotherapy solutions.MarketScreener With China representing roughly 13 percent of group sales in the period, this double-digit drop in a key growth market is a notable setback and one reason UBS expects adjusted operating profit to remain below consensus.MarketScreener The analyst commentary implies that other regions must compensate for the softer development in China if Elekta is to deliver on medium-term margin and growth ambitions.MarketScreener For shareholders, the quantified 15 percent revenue decline in China, combined with forecasts that sit 4 to 8 percent under consensus on operating profit, underscores the operational execution risk behind the recent share price strength. Radiotherapy systems as core product Elekta's business is centered on advanced radiotherapy and radiosurgery systems used in cancer treatment, complemented by software to plan and manage radiation therapy sessions. These systems generate recurring demand from hospitals and cancer centers that invest in image-guided and precision treatment solutions, and the company's exposure to markets such as China is closely tied to large-scale equipment installations and upgrade cycles.MarketScreener The reported installation delays that drove a roughly 15 percent revenue decline in China in the latest quarter therefore directly affect the timing of revenue recognition for these capital-intensive products.MarketScreener Stock near yearly high on Nasdaq Stockholm On Nasdaq Stockholm, indicative data for September 8, 2026 show Elekta stock around 16.28 SEK, compared with an indicative 52-week high near 15.95 SEK and a market capitalization of about 226 million SEK.MarketScreenerMarketScreener With the share price trading slightly above the referenced yearly high zone and up roughly 73 to 77 percent since the beginning of the year, Elekta stock presents a picture of strong market performance despite lingering fundamental risks and cautious analyst views.MarketScreener For investors, the combination of a robust share price, a narrowed valuation discount and explicit downside scenarios from UBS makes the forthcoming sector product launches and Elekta's execution in growth markets a key focus. Elekta stock key data Company: Elekta AB Elekta AB ISIN: SE0000163628 SE0000163628 Ticker: EKTA B EKTA B Trading venue: Nasdaq Stockholm Nasdaq Stockholm Price (as of September 8, 2026): 16.28 SEK 16.28 SEK Market capitalization: 226,000,000 SEK (as of September 8, 2026) 226,000,000 SEK (as of September 8, 2026) Sector / Industry: Health Care Equipment Health Care Equipment Index membership: OMX Stockholm index More news and analyses on Elekta stock